Site index: every QLogixCMC page, with the topics it answers

CMC and regulatoryMarkdown

CMC consultants for biotech and pharma: CMC strategy, CTD Module 3 authoring, control strategy, specifications, stability, post-approval changes and tech transfer.

Topics: CMC consulting · CMC consulting services · CMC regulatory consulting · CMC consultant for biotech · CTD Module 3 authoring · IND CMC section · IMPD quality section · NDA CMC

Quality systems and QMSMarkdown

QMS gap assessments, SOP development, GMP remediation and the move from paper or a legacy QMS to a validated eQMS, for biotech, pharma, CDMOs and 503B facilities.

Topics: pharmaceutical quality system consulting · QMS consulting for biotech and pharma · QMS gap assessment · GMP quality system remediation · SOP development pharma · eQMS selection and implementation · QMS digitization · ICH Q10 pharmaceutical quality system

Validation and computer software assuranceMarkdown

Validation consulting for GMP sites: CSV and CSA for computerized systems, equipment qualification, process validation and AI-enabled systems, to GAMP 5 and FDA CSA.

Topics: computer system validation consulting · CSV consulting pharma · computer software assurance consulting · FDA CSA guidance · GAMP 5 validation · validation master plan · equipment qualification IQ OQ PQ · process validation consulting

Investigations, CAPA and backlog remediationMarkdown

Deviation, OOS and complaint investigations that reach a defensible root cause, CAPAs checked for effectiveness, and aged GMP backlogs cleared to the same standard.

Topics: deviation investigation consulting · root cause analysis pharma · CAPA consulting · CAPA effectiveness check · OOS investigation FDA guidance · OOT investigation · complaint investigation pharma · deviation backlog remediation

Inspection readiness and compliance remediationMarkdown

Mock FDA and EU GMP inspections, internal and supplier audits, Form 483 and warning letter responses, data integrity audits and compliance remediation to closure.

Topics: FDA inspection readiness consulting · mock FDA inspection · pre-approval inspection readiness · GMP compliance remediation · FDA 483 response consultant · warning letter response · GMP internal audit · supplier audit pharma

GxP systems implementation and administrationMarkdown

Engineers who implement the eQMS, LIMS or MES you chose, configure it to your SOPs, migrate and validate it, and administer it for you, on site or remotely.

Topics: eQMS implementation consulting · LIMS implementation pharma · MES implementation GMP · eQMS data migration · eQMS validation · GxP system administration as a service · managed eQMS administration · outsourced QMS system administrator

AI and digital qualityMarkdown

AI governance, use-case selection, agentic workflow design, connected data and AI validation, so a GxP quality system adopts AI in a way an inspector can follow.

Topics: AI in GxP consulting · AI governance pharmaceutical quality · AI validation GAMP 5 · EU GMP Annex 22 AI · agentic workflows quality system · AI in deviation investigations · AI QMS consulting · connected quality data

BlogMarkdown

QLogixCMC on what is moving in pharma and biotech manufacturing: onshoring, CSA, AI under Annex 22, comparability, investigations. Interactive figures in every post.

Topics: pharma manufacturing blog · CMC insights · GMP compliance blog · biotech quality blog · pharma regulatory trends

Onshoring drug manufacturing: the tech transfer and validation path to a US siteMarkdown

Bringing a product to a new US site: gap analysis, qualification, method transfer, engineering and PPQ batches and PAI readiness, with an interactive timeline.

Topics: pharma onshoring · technology transfer consulting · receiving site readiness · process performance qualification · pre-approval inspection readiness · US drug manufacturing site transfer · analytical method transfer · prior approval supplement site change

AI in the GMP quality system: what Annex 22 and your next inspector will askMarkdown

EU GMP Annex 22: what the draft asks of AI in GMP, the questions inspectors already ask, and an interactive look at AI-drafted deviation investigations.

Topics: EU GMP Annex 22 · AI in GMP · AI in pharmaceutical quality system · AI validation GMP · AI deviation investigation · Annex 11 revision · AI governance pharma · human in the loop GMP

Annex 1 three years on: the contamination control strategy inspectors now read firstMarkdown

What the revised EU GMP Annex 1 asks of sterile manufacturers, where inspections find gaps, and an interactive EM trend that catches a contamination shift early.

Topics: EU GMP Annex 1 · contamination control strategy · CCS sterile manufacturing · environmental monitoring trending · contamination recovery rate · aseptic process simulation · alert and action levels · sterile injectable GMP compliance

Computer software assurance: how much testing does your system actually need?Markdown

FDA's CSA approach scales validation testing to the risk of each function. What changed from CSV, how to apply it, and an interactive estimate of the effort saved.

Topics: computer software assurance · CSA guidance FDA · CSA vs CSV · risk-based computer system validation · GAMP 5 second edition · unscripted testing GMP · validation effort reduction · Part 11 validation

Comparability for cell, gene and mRNA therapies: proving a process change left the product unchangedMarkdown

Why advanced therapies change process so often, what ICH Q5E and FDA's CGT guidance expect, and an interactive study showing why lot count decides the result.

Topics: cell therapy comparability · gene therapy comparability · mRNA comparability · ICH Q5E · comparability protocol · potency assurance strategy · CAR-T manufacturing change · AAV process change comparability

Why 21 CFR 211.192 stays the most-cited observation, and how a backlog really comes downMarkdown

What 211.192 requires, the three ways investigations fail, and an interactive burn-down showing when a deviation backlog clears and which records go first.

Topics: 21 CFR 211.192 · deviation investigation backlog · most cited FDA 483 observation · root cause human error · CAPA effectiveness · investigation backlog remediation · deviation cycle time · quality backlog burn-down